Drugdocs | Solosec®

Drug updated on 3/28/2024

Dosage Form	granules (oral: 2 g/packet)
Drug Class	Nitroimidazole antimicrobials
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

For the treatment of bacterial vaginosis in female patients 12 years of age and older.

For the treatment of trichomoniasis in patients 12 years of age and older.

Secnidazole (Solosec) is used for the treatment of bacterial vaginosis and trichomoniasis in patients 12 years of age and older.
A systematic review/meta-analysis consisting of one document was reviewed to gather information about Solosec's effectiveness against bacterial vaginosis.
The study found that a dosage of 2g secnidazole significantly reduced the risk of bacterial vaginosis in patients who had three or fewer episodes within the last year, with an odds ratio (OR) value indicating its efficacy as 7.54.
For those with four or more episodes within the same period, secnidazole also proved effective but at a lower OR value - 4.74; however, it did not increase microbiologic cure rate significantly among this group.
Comparatively, there was no significant difference between clinical cure rates from using either metronidazole (500mg bid for five days), secnidazole plus vaginal metronidazole, single dose oral metronidazol(2g), or combining secnidazol(2g) with vaginal ornidazol and just administering solosec alone at a dosage level of 2 grams.
Overall findings suggest that while both dosages levels-1 gram and two grams-of Solosec are better than placebo in treating BV, the latter proves more effective; yet when compared to other medications such as Metronidazoel, the differences were not statistically significant.

Document Title	Year	Source
Solosec (secnidazole) Prescribing Information.	2022	Lupin Pharmaceuticals Inc., Baltimore, MD

Document Title	Year	Source
Secnidazole for treatment of bacterial vaginosis: a systematic review.	2019	BMC Womens Health